Pharmaceutical Technology on MSN16d
EC approves Bavarian Nordic’s chikungunya vaccine marketing
The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine approved in Europe for individuals as young as 12 years old. Vimkunya is a virus ...
Hosted on MSN22d
Biological E Limited partners with Bavarian Nordic to increase global access to Chikungunya Vaccine
CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. While the ...
Monthly Prescribing Reference1mon
FDA Approves Vimkunya to Protect Against Chikungunya Virus
The accelerated approval was granted based on anti-CHIKV neutralizing antibody levels; continued approval may be contingent upon verification of benefit in a confirmatory trial. The Food and Drug ...
Nasdaq13d
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
About CHIKV VLP vaccineCHIKV VLP vaccine is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals ...
Indiatimes22d
Biological E in strategic pact with Danish co Bavarian Nordic to manufacture Chikungunya vax for global access
VIMKUNYA is an adjuvanted virus-like particles (VLP) recombinant protein vaccine for active immunisation of those aged 12 years and above to prevent the disease caused by the chikungunya virus.
Pharmabiz10d
UK MHRA accepts Bavarian Nordic’s MAA for chikungunya vaccine, CHIKV VLP for persons aged 12 and older
Copenhagen, Denmark Monday, March 10, 2025, 11:00 Hrs [IST] ...
Indiatimes22d
Biological E inks strategic pact with Bavarian Nordic to manufacture Chikungunya vax
Biological E (BE) has partnered with Bavarian Nordic to produce the Chikungunya vaccine, VIMKUNYA CHIKV VLP, for low and middle-income countries. The agreement aims to enhance vaccine ...
Yahoo Finance23d
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. Because VLPs ...
Yahoo Finance13d
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
CHIKV VLP vaccine was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 under the trade name VIMKUNYA ®, and could potentially obtain approval ...
Deccan Chronicle22d
Biological E Partners With Bavarian Nordic To Increase Access To Chikungunya Vaccine
About CHIKV VLP vaccine CHIKV VLP is an adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years ...
Taiwan News13d
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
Bavarian Nordic recently expanded its global commercial presence to include a dedicated UK-based organization to manage its travel health portfolio, also comprising vaccines for rabies, typhoid and ...